We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$37M
1-Year Est. Return
63.54%
This Fund
S&P 500
This Quarter
Est. Return
+32.64%
1 Year Est. Return
+63.54%
3 Year Est. Return
+38.32%
5 Year Est. Return
+47.02%
10 Year Est. Return
+2,091.28%
AUM
$37M
AUM Growth
+$22.1M
(+149%)
Cap. Flow
+$13.6M
Cap. Flow
% of AUM
36.81%
Top 10 Holdings %
Top 10 Hldgs %
92.42%
Holding
19
New
2
Increased
2
Reduced
5
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALMR
Alamar Biosciences
ALMR
|
+$17.1M |
| 2 |
Coca-Cola
KO
|
+$197K |
| 3 |
Microsoft
MSFT
|
+$4.05K |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.57K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMDX
Insight Molecular Diagnostics
IMDX
|
+$2.28M |
| 2 |
CAI
Caris Life Sciences
CAI
|
+$1.15M |
| 3 |
Natera
NTRA
|
+$213K |
| 4 |
NVIDIA
NVDA
|
+$41.1K |
| 5 |
BBNX
Beta Bionics
BBNX
|
+$1.02K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.44% |
| 2 | Technology | 5.26% |
| 3 | Financials | 1.19% |
| 4 | Communication Services | 1.15% |
| 5 | Consumer Discretionary | 0.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALMR
1
Alamar Biosciences
ALMR
$2.13B
| $20.5M | 55.35% |
+755,909
| New | +$17.1M |
|
|
BBNX
2
Beta Bionics
BBNX
$887M
| $4.41M | 11.91% |
281,164
-86
| -0% | -$1.02K |
|
3
Establishment Labs
ESTA
$2.11B
| $3.86M | 10.44% |
45,000
| – | – |
|
|
IMDX
4
Insight Molecular Diagnostics
IMDX
$135M
| $2.86M | 7.73% |
484,845
-462,289
| -49% | -$2.28M |
|
|
5
NVIDIA
NVDA
$5.25T
| $460K | 1.24% |
2,300
-200
| -8% | -$41.1K |
|
|
CAI
6
Caris Life Sciences
CAI
$7.24B
| $454K | 1.23% |
25,500
-64,440
| -72% | -$1.15M |
|
7
JPMorgan Chase
JPM
$951B
| $442K | 1.19% |
1,350
| – | – |
|
|
8
Alphabet (Google) Class C
GOOG
$4.19T
| $424K | 1.15% |
1,200
+10
| +0.8% | +$3.57K |
|
|
9
Natera
NTRA
$47B
| $407K | 1.1% |
1,500
-1,000
| -40% | -$213K |
|
10
Analog Devices
ADI
$175B
| $397K | 1.07% |
1,000
| – | – |
|
11
ASML
ASML
$651B
| $378K | 1.02% |
190
| – | – |
|
|
12
Microsoft
MSFT
$3.81T
| $373K | 1.01% |
1,000
+10
| +1% | +$4.05K |
|
13
Outset Medical
OM
$74.1M
| $360K | 0.97% |
83,333
| – | – |
|
14
Apple
AAPL
$4.67T
| $337K | 0.91% |
1,165
| – | – |
|
15
InspireMD
NSPR
$39.8M
| $315K | 0.85% |
450,517
| – | – |
|
16
Metagenomi Therapeutics
MGX
$45M
| $315K | 0.85% |
264,391
| – | – |
|
17
Amazon
AMZN
$2.87T
| $262K | 0.71% |
1,100
| – | – |
|
18
Linde
LIN
$226B
| $259K | 0.7% |
500
| – | – |
|
|
19
Coca-Cola
KO
$386B
| $203K | 0.55% |
+2,500
| New | +$197K |
|
Similar funds
MAM
GSEP
CTC
XA
YEPI
PEP
CP
WTG
Pura Vida Investments's Q2 2026 Portfolio in Review
As of Q2 2026, Pura Vida Investments held 19 positions worth $37M, up 149% from $14.9M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Pura Vida Investments deployed $13.6M of net new capital in Q2 2026, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Alamar Biosciences: 755,909 shares worth $20.5M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 81% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Insight Molecular Diagnostics, an estimated $2.28M trimmed.
- Pura Vida Investments's largest Q2 2026 buy was Alamar Biosciences: 755,909 shares worth $20.5M.
- Pura Vida Investments added most to Microsoft in Q2 2026, an estimated $4.05K increase.
- Pura Vida Investments's biggest Q2 2026 reduction was Insight Molecular Diagnostics, cutting an estimated $2.28M.
- Pura Vida Investments's ten largest holdings make up 92% of its $37M portfolio in Q2 2026.
- Pura Vida Investments opened 2 new positions and closed 0 in Q2 2026.
- Pura Vida Investments's portfolio value rose 149% quarter-over-quarter to $37M.
Based on Pura Vida Investments's 13F filing for Q2 2026, filed 13 Aug 2026.